Norovirus Infections Clinical Trial
Official title:
A Phase 1b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Oral Norovirus Vaccine Expressing GI.1 VP1 Administered Orally to Health Stable Older Adult Volunteers 55-80 Years of Age
A Phase 1b, multicenter, randomized, double-blind, placebo-controlled study to determine the safety and immunogenicity of an adenoviral-vector based oral norovirus vaccine expressing GI.1 VP1 administered orally to healthy older adult volunteers 55-80 years of age. The study is designed to assess the safety, tolerability, immunogenicity, and efficacy of 3 dose levels of vaccine with a 2-dose vaccination schedule (4 weeks apart) in healthy older adults (55 to 80 years old)
A Phase 1b, multicenter, randomized, double-blind, placebo-controlled study to determine the safety and immunogenicity of an adenoviral-vector based oral norovirus vaccine expressing GI.1 VP1 administered orally to healthy older adult volunteers 55-80 years of age. The study is designed to assess the safety, tolerability, immunogenicity, and efficacy of 3 dose levels of vaccine with a 2-dose vaccination schedule (4 weeks apart) in healthy older adults (55 to 80 years old). Subjects will we randomized in the study utilizing an age and dose escalation schedule. A Safety Monitoring Committee will provide oversight of the trial throughout the duration of the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02371538 -
Human Breastmilk in Young Children With Norovirus Infection of the Gut
|
N/A | |
| Completed |
NCT04188691 -
A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine
|
Phase 1 | |
| Recruiting |
NCT04941261 -
Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)
|
Phase 2 | |
| Not yet recruiting |
NCT05916326 -
Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)
|
Phase 3 | |
| Completed |
NCT05212168 -
Norovirus Challenge Study
|
Phase 1/Phase 2 | |
| Completed |
NCT05213728 -
A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers
|
Phase 1 | |
| Completed |
NCT06211621 -
Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 Pandemic
|
||
| Active, not recruiting |
NCT05626803 -
A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
|
Phase 2 | |
| Completed |
NCT01435811 -
Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)
|
Phase 1 | |
| Completed |
NCT04875676 -
Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines
|
Phase 1/Phase 2 |